Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : ATR04-484
Therapeutic Area : Dermatology
Study Phase : Phase I/ Phase II
Sponsor : Prosoft Clinical
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study to Evaluate Topical ATR04-484 for EGFRi-Associated Dermal Toxicity
Details : ATR04-484 is a drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Exanthema.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
February 17, 2025
Lead Product(s) : ATR04-484
Therapeutic Area : Dermatology
Highest Development Status : Phase I/ Phase II
Sponsor : Prosoft Clinical
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Recombinant Staphylococcus Epidermidis
Therapeutic Area : Dermatology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Azitra Receives Fast Track Designation for ATR-04 for Skin Rash from EGFR Inhibitors
Details : ATR-04 is a live biotherapeutic product candidate including an isolated, naturally derived Staphylococcus epidermidis strain. It is being evaluated for the treatment of EGFRi-associated skin rash.
Product Name : Undisclosed
Product Type : Microorganism
Upfront Cash : Inapplicable
September 18, 2024
Lead Product(s) : Recombinant Staphylococcus Epidermidis
Therapeutic Area : Dermatology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ATR-12
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Azitra Announces First Patient Dosed in Phase 1b Trial of ATR-12 for Netherton Syndrome
Details : ATR12-351 (ATR-12), a novel strain of S. epidermidis that has been genetically modified to express full-length protein LEKTI, being evaluated for the treatment of Netherton syndrome.
Product Name : Undisclosed
Product Type : Microorganism
Upfront Cash : Inapplicable
August 28, 2024
Lead Product(s) : ATR-12
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Recombinant Staphylococcus Epidermidis
Therapeutic Area : Dermatology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Azitra Receives FDA IND Clearance to Treat Skin Rash from EGFR Inhibitors
Details : ATR-04 is a live biotherapeutic product candidate including an isolated, naturally derived Staphylococcus epidermidis strain. It is being evaluated for the treatment of EGFRi-associated skin rash.
Product Name : Undisclosed
Product Type : Microorganism
Upfront Cash : Inapplicable
August 22, 2024
Lead Product(s) : Recombinant Staphylococcus Epidermidis
Therapeutic Area : Dermatology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ATR-12
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Azitra Screens First Patient for Phase 1b Trial of ATR-12 for Netherton Syndrome
Details : ATR12-351 (ATR-12), a novel strain of S. epidermidis that has been genetically modified to express full-length protein LEKTI, being evaluated for the treatment of Netherton syndrome.
Product Name : Undisclosed
Product Type : Microorganism
Upfront Cash : Inapplicable
August 20, 2024
Lead Product(s) : ATR-12
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ATR-12
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase I
Sponsor : Thinkequity
Deal Size : $5.0 million
Deal Type : Public Offering
Azitra, Inc. Announces Closing of Public Offering
Details : Net proceeds will fund ATR12-351 (ATR-12), a modified S. epidermidis strain expressing an active LEKTI fragment, evaluated for Netherton syndrome treatment.
Product Name : Undisclosed
Product Type : Microorganism
Upfront Cash : Undisclosed
February 16, 2024
Lead Product(s) : ATR-12
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase I
Sponsor : Thinkequity
Deal Size : $5.0 million
Deal Type : Public Offering
Lead Product(s) : ATR-12
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase I
Sponsor : Thinkequity
Deal Size : $5.0 million
Deal Type : Public Offering
Azitra, Inc. Announces Pricing of Public Offering
Details : The company intends to use the net proceeds for clinical trials and product development of ATR12-351 (ATR-12) for the treatment of Netherton Syndrome.
Product Name : Undisclosed
Product Type : Microorganism
Upfront Cash : Undisclosed
February 13, 2024
Lead Product(s) : ATR-12
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase I
Sponsor : Thinkequity
Deal Size : $5.0 million
Deal Type : Public Offering
Lead Product(s) : ATR12-351
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Evaluation of Topical ATR12-351 in Adults With Netherton Syndrome
Details : ATR12-351 is a Microorganism drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Netherton Syndrome.
Product Name : Undisclosed
Product Type : Microorganism
Upfront Cash : Inapplicable
November 18, 2023
Lead Product(s) : ATR12-351
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ATR-12
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase I
Sponsor : Thinkequity
Deal Size : $7.5 million
Deal Type : Public Offering
Azitra, Inc. Announces Closing of Initial Public Offering
Details : The company intends to use the net proceeds for clinical trials and product development of ATR-12, a proprietary strain of Staphylococcus epidermidis engineered to express therapeutic levels of LEKTI protein to treat netherton syndrome.
Product Name : Undisclosed
Product Type : Microorganism
Upfront Cash : Undisclosed
June 21, 2023
Lead Product(s) : ATR-12
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase I
Sponsor : Thinkequity
Deal Size : $7.5 million
Deal Type : Public Offering
Lead Product(s) : Strain of Staphylococcus Epidermidis
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase I
Sponsor : Thinkequity
Deal Size : $7.5 million
Deal Type : Public Offering
Azitra, Inc. Announces Pricing of Initial Public Offering
Details : The Company intends to use the net proceeds for clinical trials and product development of ATR-12, a proprietary strain of Staphylococcus epidermidis engineered to express therapeutic levels of LEKTI protein to treat netherton syndrome.
Product Name : Undisclosed
Product Type : Probiotic
Upfront Cash : Undisclosed
June 15, 2023
Lead Product(s) : Strain of Staphylococcus Epidermidis
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase I
Sponsor : Thinkequity
Deal Size : $7.5 million
Deal Type : Public Offering